陈艺,颜红兵

• 1:北京首都医科大学附属北京安贞医院心内科28病区
• 2:中国医学科学院北京协和医学院北京阜外心血管病医院冠心病诊治中心15病区

摘要(Abstract)：

<正>无复流是指心外膜冠脉闭塞减轻或解除后,缺血心肌组织并没有恢复有效再灌注,微循环血流仍不能完全恢复正常的现象[1]。无复流分为:(1)实验性无复流:实验条件下通过制作急性心肌缺血再灌注模型观察到的无复流。(2)心

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈艺,颜红兵

参考文献(References)：

• [1]Rezkalla SH,Kloner RA.Coronary no-reflow phenomenon:from the experimental laboratory to the cardiac catheterization laboratory.Catheter Cardiovasc Interv,2008,72:950-957.
• [2]Eeckhout E,Kern MJ.The coronary no-reflow phenomenon:a review of mechanisms and therapies.Eur Heart J,2001,22:729-739.
• [3]Carrabba N,Parodi G,Valenti R,et al.Significance of additional ST segment elevation in patients with no reflow after angioplasty for acute myocardial infarction.J Am Soc Echocardiogr,2007,20:262-269.
• [4]van der Wal AC,Li X,de Boer OJ.Tissue factor expression in the morphologic spectrum of vulnerable atherosclerotic plaques.Semin Thromb Hemost,2006,32:40-47.
• [5]Croce K,Libby P.Intertwining of thrombosis and inflammation in atherosclerosis.Curr Opin Hematol,2007,14:55-61.
• [6]Chandra KS,Kumar R,Shankar SJ.Angioplasty of degenerated saphenous vein grafts--role of covered stents.J Indian Med Assoc,2007,105:37-41.
• [7]Steffel J,Luscher TF,Tanner FC.Tissue factor in cardiovascular diseases:molecular mechanisms and clinical implications.Circulation,2006,113:722-731.
• [8]Gando S.Tissue factor in trauma and organ dysfunction.Semin Thromb Hemost,2006,32:48-53.
• [9]Gross GJ,Auchampach JA.Reperfusion injury:does it exist J Mol Cell Cardiol,2007,42:12-18.
• [10]Zhou H,Liu J,Pan P,et al.Carbon monoxide inhalation decreased lung injury via anti-inflammatory and anti-apoptotic effects in brain death rats.Exp Biol Med(Maywood),2010,235:1236-1243.
• [11]Aggarwal A,Schneider DJ,Terrien EF,et al.Increased coronary arterial release of interleukin-1receptor antagonist and soluble CD40ligand indicative of inflammation associated with culprit coronary plaques.Am J Cardiol,2004,93:6-9.
• [12]Hansson GK.Inflammation,atherosclerosis,and coronary artery disease.N Engl J Med,2005,352:1685-1695.
• [13]Lucas AR,Korol R,Pepine CJ.Inflammation in atherosclerosis:some thoughts about acute coronary syndromes.Circulation,2006,113:e728-e732.
• [14]Wang Y,Schmeichel AM,Iida H,et al.Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury.J Neurol Sci,2006,247:47-52.
• [15]Sethi G,Sung B,Aggarwal BB.Nuclear factor-kappaB activation:from bench to bedside.Exp Biol Med(Maywood),2008,233:21-31.
• [16]Thiemermann C.Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size.Cardiovasc Res,2004,63:8-10.
• [17]Laga M,Cottyn A,Van Herreweghe F,et al.Methylglyoxal suppresses TNF-alpha-induced NF-kappaB activation by inhibiting NF-kappaB DNA-binding.Biochem Pharmacol,2007,74:579-589.
• [18]Sgueglia GA,Niccoli G,Spaziani C,et al.Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction.Int J Cardiol,2010,145:230-232.
• [19]Zhang C,Xu X,Potter BJ,et al.TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury.Arterioscler Thromb Vasc Biol,2006,26:475-480.
• [20]Ndrepepa G,Tiroch K,Keta D,et al.Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.Circ Cardiovasc Interv,2010,3:27-33.
• [21]Welsh P,Woodward M,Rumley A,et al.Associations of circulating TNFalpha and IL-18with myocardial infarction and cardiovascular risk markers:the Glasgow Myocardial Infarction Study.Cytokine,2009,47:143-147.
• [22]Kern KB,Berg RA,Hilwig RW,et al.Myocardial cytokine IL-8and nitric oxide synthase activity during and after resuscitation:preliminary observations in regards to post-resuscitation myocardial dysfunction.Resuscitation,2008,77:401-409.
• [23]Mannila MN,Eriksson P,Leander K,et al.The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL-6concentration.J Intern Med,2007,261:138-147.
• [24]Rodondi N,Marques-Vidal P,Butler J,et al.Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults.Am J Epidemiol,2010,171:540-549.
• [25]Lopes RD,Batista JM,Rosa JC,et al.Changes in the production of IL-10and TNF-alpha in skeletal muscle of rats with heart failure secondary to acute myocardial infarction.Arq Bras Cardiol,2010,94:293-300,313-320.
• [26]Krishnamurthy P,Rajasingh J,Lambers E,et al.IL-10inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3and suppression of HuR.Circ Res,2009;104:e9-e18.
• [27]Yellon DM,Hausenloy DJ.Myocardial reperfusion injury.N Engl J Med,2007,357:1121-1135.
• [28]Niccoli G,Giubilato S,Russo E,et al.Plasma levels of thromboxane A2on admission are associated with no-reflow after primary percutaneous coronary intervention.Eur Heart J,2008,29:1843-1850.
• [29]Eitel I,Nowak M,Stehl C,et al.Endothelin-1release in acute myocardial infarction as a predictor of long-termprognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.Am Heart J,2010,159:882-890.
• [30]Niccoli G,Lanza GA,Shaw S,et al.Endothelin-1and acute myocardial infarction:a no-reflow mediator after successful percutaneous myocardial revascularization.Eur Heart J,2006,27:1793-1798.
• [31]Topsakal R,Kaya MG,Karakaya E,et al.Relationship between no-reflow phenomenon and serotonin levels in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous intervention.Anadolu Kardiyol Derg,2010,10:253-259.
• [32]Takahashi T,Hiasa Y,Ohara Y,et al.Relation between neutrophil counts on admission,microvascular injury,and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty.Am J Cardiol,2007,100:35-40.
• [33]Mangiacapra F,Muller O,Ntalianis A,et al.Comparison of600versus300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.Am J Cardiol,2010,106:1208-1211.
• [34]Campo G,Valgimigli M,Gemmati D,et al.Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention:insights into the STRATEGY Study.J Am Coll Cardiol,2006,48:2178-2185.
• [35]Kelbaek H,Terkelsen CJ,Helqvist S,et al.Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention:the drug elution and distal protection in ST-elevation myocardial infarction(DEDICATION)trial.J Am Coll Cardiol,2008,51:899-905.
• [36]Huczek Z,Kochman J,Filipiak KJ,et al.Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention.J Am Coll Cardiol,2005,46:284-290.
• [37]Skyschally A,Leineweber K,Gres P,et al.Coronary microembolization.Basic Res Cardiol,2006,101:373-382.
• [38]Pasceri V,Pristipino C,Pelliccia F,et al.Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.Am J Cardiol,2005,95:1358-1361.
• [39]Wu H,Dong G,Liu H,et al.Erythropoietin attenuates ischemia-reperfusion induced lung injury by inhibiting tumor necrosis factor-alpha and matrix metalloproteinase-9expression.Eur J Pharmacol,2009,602:406-412.
• [40]Haeck JD,Verouden NJ,Kuijt WJ,et al.Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Am J Cardiol,2010;105:1065-1069.